PUT - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Borsa Italiana 04:04:59 2024-07-12 pm EDT | ||
| 4.19 EUR | -3.90% |
|
| Current month | +7.69% | ||
| 1 month | +3.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 4.2 | -3.67% |
| 24-07-11 | 4.36 | +5.06% |
| 24-07-10 | 4.15 | -3.94% |
| 24-07-09 | 4.32 | +6.67% |
| 24-07-08 | 4.05 | -1.94% |
Real-time Borsa Italiana
Last update July 12, 2024 at 04:04 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| F48997 | |
| ISIN | DE000VD7CLR1 |
| Date issued | 2024-06-12 |
| Strike | 1,282 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.57 € |
|---|---|
| Lowest since issue | 3.33 € |
| Spread | 0.14 € |
| Spread % | 3.33% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
980.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-2.43%
- Stock Market
- Certificates
- F48997 Certificat
